KabaFusion

KabaFusion, founded in 2010, has positioned itself as a leading provider of patient-focused infusion therapy in the health care industry. The company's multidisciplinary team approach ensures continuity of care for patients transitioning from hospitals to their homes.

KabaFusion's commitment to patient care is evident through its 24/7 on-call pharmacist and nurse services, specialized in infusion therapy. The company is known for expertise in intravenous immune globulin (IVIG) therapy and other specialty pharmacy needs, ensuring optimal patient care.

With a national presence and strategically located facilities, KabaFusion provides easy access to its products and services throughout the United States. The company's mission emphasizes a dedication to positive clinical outcomes and excellence in specialty acute and immunoglobulin infusion, supported by proactive collaboration with patients, healthcare practitioners, and payers.

The recent Private Equity Round investment on 01 November 2022, led by Churchill Asset Management, signifies external validation and potential growth opportunities for KabaFusion. The investment reinforces the company's position and outlook, reflecting confidence in its patient-focused approach and specialized services.

Overall, KabaFusion's strong focus on patient care, professional expertise, and strategic partnerships positions it as a promising player in the health care industry, with potential for significant growth and impact in the future.